121 related articles for article (PubMed ID: 33902050)
1. Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis.
Dong G; Chen H; Zhang H; Gu Y
Cardiology; 2021; 146(4):433-440. PubMed ID: 33902050
[TBL] [Abstract][Full Text] [Related]
2. Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis.
Gu L; Li J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31092701
[No Abstract] [Full Text] [Related]
3. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis.
Aimo A; Vergaro G; Passino C; Ripoli A; Ky B; Miller WL; Bayes-Genis A; Anand I; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):280-286. PubMed ID: 27816512
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.
Aimo A; Vergaro G; Ripoli A; Bayes-Genis A; Pascual Figal DA; de Boer RA; Lassus J; Mebazaa A; Gayat E; Breidthardt T; Sabti Z; Mueller C; Brunner-La Rocca HP; Tang WH; Grodin JL; Zhang Y; Bettencourt P; Maisel AS; Passino C; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):287-296. PubMed ID: 28189578
[TBL] [Abstract][Full Text] [Related]
5. The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis.
Liu N; Hang T; Gao X; Yang W; Kong W; Lou Q; Yang J
PLoS One; 2020; 15(9):e0238775. PubMed ID: 32886697
[TBL] [Abstract][Full Text] [Related]
6. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis.
Guo G; Huang A; Huang X; Xu T; Yao L
Dis Markers; 2021; 2021():8881393. PubMed ID: 33574967
[TBL] [Abstract][Full Text] [Related]
8. Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2.
Somuncu MU; Kalayci B; Avci A; Akgun T; Karakurt H; Demir AR; Avci Y; Can M
Horm Mol Biol Clin Investig; 2020 Feb; 41(2):. PubMed ID: 32112700
[TBL] [Abstract][Full Text] [Related]
9. Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study.
Wang Z; Chen Z; Yu H; Ma X; Zhang C; Qu B; Zhang W; Chen X
Ren Fail; 2020 Nov; 42(1):523-530. PubMed ID: 32460670
[No Abstract] [Full Text] [Related]
10. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure.
Gül İ; Yücel O; Zararsız A; Demirpençe Ö; Yücel H; Zorlu A; Yılmaz MB
Anatol J Cardiol; 2017 Sep; 18(3):200-205. PubMed ID: 28761021
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction.
Wang Z; Qin Z; Yuan R; Guo J; Xu S; Lv Y; Xu Y; Lu Y; Gao J; Yu F; Tang L; Zhang L; Bai J; Cui X; Zhang J; Tang J
ESC Heart Fail; 2023 Feb; 10(1):478-491. PubMed ID: 36316302
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective.
Jenkins WS; Roger VL; Jaffe AS; Weston SA; AbouEzzeddine OF; Jiang R; Manemann SM; Enriquez-Sarano M
Am J Med; 2017 Sep; 130(9):1112.e9-1112.e15. PubMed ID: 28344136
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
[TBL] [Abstract][Full Text] [Related]
14. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure.
Binas D; Daniel H; Richter A; Ruppert V; Schlüter KD; Schieffer B; Pankuweit S
Open Heart; 2018; 5(1):e000750. PubMed ID: 29531765
[TBL] [Abstract][Full Text] [Related]
16. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
17. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study.
Dieplinger B; Egger M; Haltmayer M; Kleber ME; Scharnagl H; Silbernagel G; de Boer RA; Maerz W; Mueller T
Clin Chem; 2014 Mar; 60(3):530-40. PubMed ID: 24401186
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - A multicenter study.
Bahuleyan CG; Alummoottil GK; Abdullakutty J; Lordson AJ; Babu S; Krishnakumar VV; Pillai AM; Abraham G; Dilip MN
Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S79-S84. PubMed ID: 30122243
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
20. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and
Ip C; Luk KS; Yuen VLC; Chiang L; Chan CK; Ho K; Gong M; Lee TTL; Leung KSK; Roever L; Bazoukis G; Lampropoulos K; Li KHC; Tse G; Liu T;
Int J Cardiol Heart Vasc; 2021 Dec; 37():100887. PubMed ID: 34712771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
